Home

Articles from ZIVO Bioscience, Inc.

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
By ZIVO Bioscience, Inc. · Via Business Wire · February 6, 2025
ZIVO Bioscience to Present at The Microcap Conference 2025
Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
By Zivo Bioscience, Inc. · Via Business Wire · January 22, 2025
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens.
By Zivo Bioscience, Inc. · Via Business Wire · December 23, 2024
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
By Zivo Bioscience, Inc. · Via Business Wire · December 20, 2024
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens.
By ZIVO Bioscience, Inc. · Via Business Wire · August 23, 2024
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
ZIVO Bioscience, Inc. (NASDAQZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company.
By ZIVO Bioscience, Inc. · Via Business Wire · July 8, 2024
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
By Zivo Bioscience, Inc. · Via Business Wire · February 7, 2024
ZIVO Bioscience Announces Uplisting to OTCQB Market
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience continues to trade under the ticker symbol “ZIVO” and warrants continue to trade under the ticker symbol “ZIVOW”.
By Zivo Bioscience, Inc. · Via Business Wire · January 29, 2024
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product.
By Zivo Bioscience, Inc. · Via Business Wire · January 23, 2024
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens.
By Zivo Bioscience, Inc. · Via Business Wire · October 30, 2023
ZIVO Bioscience Announces Reverse Stock Split
Zivo Bioscience, Inc. (NASDAQZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023 (the “Effective Time”). The Company’s Common Stock will begin trading on a split-adjusted basis on October 27, 2023 and will continue to trade on the Nasdaq Capital Market under the existing symbol “ZIVO.” The new CUSIP number for the Common Stock following the reverse split is US98978N3098.
By Zivo Bioscience, Inc. · Via Business Wire · October 26, 2023
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Fla.
By Zivo Bioscience, Inc. · Via GlobeNewswire · October 3, 2023
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups.
By Zivo Bioscience, Inc. · Via Business Wire · September 19, 2023
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
Zivo Bioscience, Inc. (NASDAQZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on the commercialization of Zivolife, its proprietary algal biomass as a food or food ingredient.
By Zivo Bioscience, Inc. · Via Business Wire · August 16, 2023
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
Zivo Bioscience, Inc. (NASDAQZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient.
By Zivo Bioscience, Inc. · Via Business Wire · July 26, 2023
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market
Zivo Bioscience, Inc. (NASDAQZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,498,130 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell to the investor Series A warrants to purchase up to an aggregate of 1,498,130 shares of common stock and Series B warrants to purchase up to an aggregate of 1,498,130 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying Series A and Series B warrant is $2.67.
By Zivo Bioscience, Inc. · Via Business Wire · June 30, 2023
ZIVO’s GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as a Human Food Ingredient
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced it has received an updated dossier from an independent scientific review panel reconfirming the Company’s “Generally Recognized As Safe” (GRAS) designation for its proprietary algal biomass to be marketed and used as an ingredient in a defined range of foods and beverages for human consumption.
By Zivo Bioscience, Inc. · Via Business Wire · May 30, 2023
ZIVO Bioscience Receives $1 Million Bridge Financing
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne. The loan carries 10% simple interest, may be prepaid without penalty, is extendable for an additional six months and includes warrants to purchase 390,000 shares of ZIVO common stock with a strike price of $2.91 per share. More information on the loan and warrants is available in ZIVO’s Form 8-K filed today with the SEC.
By Zivo Bioscience, Inc. · Via Business Wire · April 5, 2023
ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.
By Zivo Bioscience, Inc. · Via Business Wire · February 10, 2023
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
Zivo Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC (“ZIVOLife”), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company’s proprietary algae biomass.
By Zivo Bioscience, Inc. · Via Business Wire · October 24, 2022
ZIVO Bioscience CEO Issues Letter to Shareholders
Zivo Bioscience, Inc. (NASDAQZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
By Zivo Bioscience, Inc. · Via Business Wire · September 23, 2022
ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment
ZIVO Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces receipt of a letter from the U.S. Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens.
By ZIVO Bioscience, Inc. · Via Business Wire · August 10, 2022
Zivo Bioscience Joins Russell Microcap® Index
ZIVO Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual reconstitution.
By ZIVO Bioscience, Inc. · Via Business Wire · June 27, 2022
Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq
ZIVO Bioscience, Inc. (NASDAQZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice from Nasdaq that the Company has regained compliance of Nasdaq Listing Rule 5250(c)(1).
By ZIVO Bioscience, Inc. · Via Business Wire · April 25, 2022
ZIVO Bioscience Names Chairman John B. Payne as President and CEO
ZIVO Bioscience, Inc. (NASDAQZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Board John B. Payne has been named President and Chief Executive Officer of the Company. Mr. Payne succeeds Andrew A. Dahl.
By ZIVO Bioscience, Inc. · Via Business Wire · January 10, 2022